edoxaban
Savaysa (edoxaban) is an oral factor Xa inhibitor from Daiichi Sankyo. By blocking one central step of the clotting cascade it reduces stroke risk in atrial fibrillation and treats deep vein thrombosis and pulmonary embolism after initial injectable therapy.
This page is based on FDA prescribing information and the EMA medicine record for edoxaban, cross-checked with DailyMed and MedlinePlus; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
A clot forms like a relay race in which each clotting factor hands a baton to the next, and factor Xa runs the decisive leg just before the finish line. Edoxaban takes factor Xa out of the race, so the baton never reaches the end and the clot is never completed.
In simple terms
Blood clotting depends on a chain reaction of proteins, and factor Xa sits at a key point in that chain, helping make thrombin, which builds the clot. Edoxaban directly inhibits factor Xa, so less thrombin is produced and fewer clots form. This protects against stroke in people with atrial fibrillation and treats existing clots in the legs and lungs.
In depth
Edoxaban is a selective, competitive, reversible direct inhibitor of factor Xa with high oral bioavailability. It inhibits free and clot-bound factor Xa and prothrombinase complex activity, reducing thrombin generation without directly affecting thrombin or platelet aggregation. Dose selection accounts for renal function and body weight, and it requires no routine coagulation monitoring.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How edoxaban directly inhibits factor Xa
- A clot forms like a relay race in which each clotting factor hands a baton to the next, and factor Xa runs the decisive leg just before the finish line.
- Edoxaban is a selective, competitive, reversible direct inhibitor of factor Xa with high oral bioavailability.
- It inhibits free and clot-bound factor Xa and prothrombinase complex activity, reducing thrombin generation without directly affecting thrombin or platelet aggregation.
- Dose selection accounts for renal function and body weight, and it requires no routine coagulation monitoring.
Target: Coagulation factor Xa
The clotting enzyme that converts prothrombin to thrombin at the convergence point of the cascade; inhibiting it reduces thrombin generation and new clot formation.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
- Treatment of deep vein thrombosis and pulmonary embolism following 5 to 10 days of initial therapy with a parenteral anticoagulant
Approved uses in European Union
EMA- Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus or prior stroke or transient ischaemic attack
- Treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism, in adults
Official sources
The statements on this page trace back to these records.
- Lixiana (edoxaban) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: Savaysa (edoxaban) label
DailyMed, U.S. National Library of Medicine
- U.S. Food and Drug Administration: edoxaban prescribing information
U.S. Food and Drug Administration
- MedlinePlus: edoxaban
MedlinePlus, U.S. National Library of Medicine
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.